Ricky Frazer, Consultant Medical Oncologist at Velindre Cancer Centre, Deputy CEO of the Immuno-Oncology Clinical Network, Co-Founder of The Immunobuddies Podcast and Honorary Lecturer at Cardiff University, shared a post on LinkedIn:
“Really looking forward to this one. 1 week to go!
Delighted to be speaking at the International Kidney Cancer Symposium (IKCS) Europe 2026 alongside Laurence Albiges and Cristina Suárez on a topic that’s becoming increasingly complex – and increasingly important:
How do we truly select treatment in favourable-risk mRCC?
For years, this space felt relatively straightforward. Now… not so much.
We’re navigating:
- Single-agent IO.
- IO/TKI doublets.
- Emerging triplet strategies.
- And a growing body of data that doesn’t always point in the same direction.
The challenge isn’t a lack of options – it’s making the right choice for the patient in front of you.
This session will focus on:
– Interpreting the latest evidence (and what actually matters).
– Understanding where triplets might fit (if at all).
– Real-world decision making vs trial populations.
– And where the field is heading next.
- Paris Marriott Rive Gauche.
- Thursday 16 April.
- 17:00-18:00 CEST.
If you’re at IKCS Europe, come along – should be a really lively discussion.”
Other articles about mRCC on OncoDaily.